Media Contact
Annette Ballou
Email
216.658.3999
|
|
Newsroom > News
|
|
|
Theravasc, a biotech company that has relocated to Cleveland, announced equity investments of $500,000 from funding sources, JumpStart and Portal Capital. Funds will be used to begin a pharmacokenetic study of Theravasc's reformulated sodium nitrate to treat peripheral arterial disease in diabetic patients.
Click here to read more from MedCity News.
|
|
|
|